September 19, 2015 4:40 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
T2 Biosystems, Inc. (NASDAQ: TTOO) today announced that data on its T2Candida® Panel was presented today at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, CA. The data demonstrate that T2Candida is more sensitive and rapid than blood culture for monitoring invasive candidiasis in proven cases of infection. "This study was designed to take repeated blood samples from patients over time to determine the sensitivity of T2Candida compared to blood culture for monitoring patients on antifungal therapy," said Peter Pappas, M.D., FACP, professor of medicine, division of infectious diseases, University of Alabama at Birmingham and principal investigator of the study. "The findings indicate that T2Candida may be a useful tool for monitoring patients and could facilitate initiation of cessation of therapy as well as improving source control." "Previous studies have demonstrated that blood culture may yield false negative test results when patients are on antifungal therapy," said John McDonough, president and CEO of T2 Biosystems. "The results from this study demonstrate that T2Candida can provide more accurate results for patients who
See full press release
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.